{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:52:48Z","timestamp":1791265968041,"version":"4.1.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2020,12,21]],"date-time":"2020-12-21T00:00:00Z","timestamp":1608508800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatol. Commun."],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:p>This study describes the design of the TARGET\u2010hepatocellular carcinoma (HCC) cohort and descriptive characteristics of the patient population at diagnosis among those who were enrolled in the cohort across academic and community clinical centers. TARGET\u2010HCC is a 5\u2010year, longitudinal, observational cohort of patients with HCC receiving care in usual clinical practice. Redacted clinical information, obtained from medical records, captures the natural history and management of the disease, including the safety and efficacy of treatment interventions used in usual clinical practice. Patients can complete patient\u2010reported outcome measures and provide biological specimens for future translational studies. The TARGET\u2010HCC study includes adults with histologic, cytologic, or radiologic diagnosis of HCC from academic and community centers in both the United\u00a0States and Europe. A total of 1,841 participants were enrolled between January 9, 2017, and July 23, 2019, at 67 sites in the United States and Europe. To date, the most common liver disease etiology in the cohort continues to be hepatitis C, although nearly half had a nonviral etiology, including alcohol\u2010related liver disease or nonalcoholic steatohepatitis. Most included patients were diagnosed at an early stage (Barcelona Clinic Liver Cancer Stage [BCLC] 0\/A), but only approximately one third underwent curative treatment. Systemic therapy has been used in 7.3% of enrolled patients, including 45.7% of those with BCLC stage C tumors. <jats:italic toggle=\"yes\">Conclusion:<\/jats:italic> Overall, the TARGET\u2010HCC cohort allows for the assessment of patient characteristics and investigation of new treatment paradigms and sequencing with existing agents as well as novel regimens for HCC.<\/jats:p>","DOI":"10.1002\/hep4.1652","type":"journal-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T02:40:46Z","timestamp":1608604846000},"page":"538-547","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["A Real\u2010World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET\u2010HCC"],"prefix":"10.1097","volume":"5","author":[{"given":"Roniel","family":"Cabrera","sequence":"first","affiliation":[{"name":"University of Florida,Gainesville,FL,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit G.","family":"Singal","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center,Dallas,TX,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Colombo","sequence":"additional","affiliation":[{"name":"Center for Translational Research in Liver Disease,Humanitas Hospital,Rozzano,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.\u00a0Kate","family":"Kelley","sequence":"additional","affiliation":[{"name":"University of California San Francisco,San Francisco,CA,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology and Nutrition,Virginia Commonwealth University,Richmond,VA,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3419-8276","authenticated-orcid":false,"given":"Andrea R.","family":"Mospan","sequence":"additional","affiliation":[{"name":"Target RWE,Durham,NC,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Meyer","sequence":"additional","affiliation":[{"name":"Royal Free Hospital and University College London Cancer Institute,University College London,London,United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pippa","family":"Newell","sequence":"additional","affiliation":[{"name":"The Oregon Clinic,Portland,OR,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neehar D.","family":"Parikh","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine,University of Michigan,Ann Arbor,MI,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Sangro","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine,Clinica Universidad de Navarra,Madrid,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4898-7778","authenticated-orcid":false,"given":"K. Rajender","family":"Reddy","sequence":"additional","affiliation":[{"name":"Department of Medicine,University of Pennsylvania,Philadelphia,PA,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Watkins","sequence":"additional","affiliation":[{"name":"Target RWE,Durham,NC,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard C.","family":"Zink","sequence":"additional","affiliation":[{"name":"Target RWE,Durham,NC,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian M.","family":"Di Bisceglie","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,St. Louis University,St. Louis,MO,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,12,21]]},"reference":[{"key":"hep41652-bib-0001-20241015","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"hep41652-bib-0002-20241015","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma","volume":"380","year":"2019","journal-title":"N Engl J Med"},{"key":"hep41652-bib-0003-20241015","article-title":"Annual Report to the Nation on the Status of Cancer, 1975\u20102014, featuring survival","volume":"109","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"hep41652-bib-0004-20241015","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1053\/j.gastro.2008.09.014","article-title":"Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C\u2010related advanced liver disease","volume":"136","year":"2009","journal-title":"Gastroenterology"},{"key":"hep41652-bib-0005-20241015","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.cgh.2018.05.057","article-title":"Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates","volume":"17","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep41652-bib-0006-20241015","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: trends, risk, prevention and management","volume":"16","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"hep41652-bib-0007-20241015","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases","volume":"68","year":"2018","journal-title":"Hepatology"},{"key":"hep41652-bib-0008-20241015","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: Management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"hep41652-bib-0009-20241015","article-title":"Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta\u2010analysis","volume":"11","year":"2014","journal-title":"PLoS Med"},{"key":"hep41652-bib-0010-20241015","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","year":"2008","journal-title":"N Engl J Med"},{"key":"hep41652-bib-0011-20241015","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first\u2010line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non\u2010inferiority trial","volume":"391","year":"2018","journal-title":"Lancet"},{"key":"hep41652-bib-0012-20241015","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double\u2010blind, placebo\u2010controlled, phase 3 trial","volume":"389","year":"2017","journal-title":"Lancet"},{"key":"hep41652-bib-0013-20241015","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","year":"2018","journal-title":"N Engl J Med"},{"key":"hep41652-bib-0014-20241015","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha\u2010fetoprotein concentrations (REACH\u20102): a randomised, double\u2010blind, placebo\u2010controlled, phase 3 trial","volume":"20","year":"2019","journal-title":"Lancet Oncol"},{"key":"hep41652-bib-0015-20241015","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open\u2010label, non\u2010comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","year":"2017","journal-title":"Lancet"},{"key":"hep41652-bib-0016-20241015","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE\u2010224): a non\u2010randomised, open\u2010label phase 2 trial","volume":"19","year":"2018","journal-title":"Lancet Oncol"},{"key":"hep41652-bib-0017-20241015","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab As Second\u2010Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE\u2010240: A Randomized, Double\u2010Blind, Phase III Trial","volume":"38","year":"2020","journal-title":"J Clin Oncol"},{"key":"hep41652-bib-0018-20241015","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","year":"2020","journal-title":"N Engl J Med"},{"key":"hep41652-bib-0019-20241015","article-title":"A primer on effectiveness and efficacy trials","volume":"5","year":"2014","journal-title":"Clin Transl Gastroenterol"},{"key":"hep41652-bib-0020-20241015","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cct.2017.07.015","article-title":"Design and rationale for a real\u2010world observational cohort of patients with nonalcoholic fatty liver disease: the TARGET\u2010NASH study","volume":"61","year":"2017","journal-title":"Contemp Clin Trials"},{"key":"hep41652-bib-0021-20241015","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s11136-010-9619-3","article-title":"An item response analysis of the pediatric PROMIS anxiety and depressive symptoms scales","volume":"19","year":"2010","journal-title":"Qual Life Res"},{"key":"hep41652-bib-0022-20241015","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: the BCLC staging classification","volume":"19","year":"1999","journal-title":"Semin Liver Dis"},{"key":"hep41652-bib-0023-20241015","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","year":"1996","journal-title":"N Engl J Med"},{"key":"hep41652-bib-0024-20241015","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.cgh.2015.07.010","article-title":"Development and performance of an algorithm to estimate the Child\u2010Turcotte\u2010Pugh Score from a national electronic healthcare database","volume":"13","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep41652-bib-0025-20241015","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"hep41652-bib-0026-20241015","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1097\/MLR.0b013e318268aaff","article-title":"The use of patient\u2010reported outcomes (PRO) within comparative effectiveness research: implications for clinical practice and health care policy","volume":"50","year":"2012","journal-title":"Med Care"},{"key":"hep41652-bib-0027-20241015","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/bjs.1800600817","article-title":"Transection of the oesophagus for bleeding oesophageal varices","volume":"60","year":"1973","journal-title":"Br J Surg"}],"updated-by":[{"DOI":"10.1002\/hep4.1868","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000}}],"container-title":["Hepatology Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep4.1652","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep4.1652","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep4.1652","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T22:15:09Z","timestamp":1729030509000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep4.1652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,21]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1002\/hep4.1652","relation":{"correction":[{"id-type":"doi","id":"10.1002\/hep4.1868","asserted-by":"object"}]},"ISSN":["2471-254X","2471-254X"],"issn-type":[{"value":"2471-254X","type":"print"},{"value":"2471-254X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,21]]},"assertion":[{"value":"2020-08-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}